Skip to content

Drug interactions

Idarubicin + Tucatinib

Severity: Moderate

Idarubicin and Tucatinib: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Tucatinib inhibits P-glycoprotein and may raise exposure to idarubicin, which is a P-gp substrate. Higher anthracycline levels could worsen myelosuppression and cardiotoxicity.

What this interaction means in plain words

Idarubicin and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Idarubicin belongs to Oncology; Tucatinib belongs to Oncology.

Evidence level: Low

Why it happens

Tucatinib inhibits P-glycoprotein efflux, reducing idarubicin transport and increasing its systemic exposure.

What to do

Monitor blood counts and cardiac function closely when the two are combined. Consider idarubicin dose reduction if marked toxicity develops.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Idarubicin and Tucatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Idarubicin with Tucatinib?

MediHelp rates the interaction as moderate. Idarubicin and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tucatinib inhibits P-glycoprotein and may raise exposure to idarubicin, which is a P-gp substrate. Higher anthracycline levels could worsen myelosuppression and cardiotoxicity.

How serious is the interaction between Idarubicin and Tucatinib?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function closely when the two are combined. Consider idarubicin dose reduction if marked toxicity develops.

What other medicines interact with Idarubicin?

MediHelp also lists interactions of Idarubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cyclophosphamide. The full list is on the Idarubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in